Ceapro Revenue and Competitors

Location

$1.7M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Ceapro's estimated annual revenue is currently $3.6M per year.(i)
  • Ceapro's estimated revenue per employee is $77,500
  • Ceapro's total funding is $1.7M.

Employee Data

  • Ceapro has 46 Employees.(i)
  • Ceapro grew their employee count by 7% last year.

Ceapro's People

NameTitleEmail/Phone
1
CFOReveal Email/Phone
2
Controller and Human ResourcesReveal Email/Phone
3
VP, Bioprocessing Business UnitReveal Email/Phone
4
VP Bioprocessing and Account ManagementReveal Email/Phone
5
Director, Scientific Affairs and New Business DevelopmentReveal Email/Phone
6
Chief Revenue OfficerReveal Email/Phone
7
Director Innovation and Product DevelopmentReveal Email/Phone
8
Senior Director, Research & TechnologyReveal Email/Phone
9
Manager, Financial ReportingReveal Email/Phone
10
Research ScientistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.6M100%N/AN/A
#2
$3.6M467%$1.7MN/A
#3
$2.5M3214%N/AN/A
#4
$3.4M44-4%N/AN/A
#5
$11.8M7641%N/AN/A
#6
$3.6M23-4%N/AN/A
#7
$1.2M160%N/AN/A
#8
$4.5M29-9%N/AN/A
#9
$3.1M2033%N/AN/A
#10
$0.7M9-25%N/AN/A
Add Company

What Is Ceapro?

Ceapro Inc. is a Canadian biotechnology company involved in the development and commercialization of “active ingredients” derived from oats and other renewable plant resources for healthcare and cosmetic industries. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. Ceapro’s patented process technologies include its Pressurized Gas eXpanded (PGX) technology which is a unique and disruptive technology with several key advantages over conventional drying and purification methods that can be used to process biopolymers into high-value, nano-sized polymer structures and novel bio-nanocomposites. Ceapro also utilizes its proprietary plant extraction-based manufacturing process to supply ingredients to well-known personal care and cosmetic industries worldwide. The Company’s two value-driving products, oat beta glucan and avenanthramides, are found in many household names, cosmetic and personal care brands. These products are manufactured from Ceapro’s proprietary oat extraction manufacturing technology and are known for their well-documented health benefits. Oat beta glucan effectively stimulates collagen synthesis and deeply moisturizes the skin (epidermis and dermis) thereby improving skin restructuring, decreasing wrinkles and allowing wound healing with minimal scaring. When taken orally, oat beta glucan has been shown to improve cholesterol levels and therefore has “heart health” approved health claims in Canada, United States and Europe. Avenanthramides are polyphenolic compounds found exclusively in oats which act as natural anti-oxidant, anti-irritant and anti-inflammatory. When added to topical formulation, avenanthramides effectively reduce redness and itchiness due to inflammation. In oral formulations, avenanthramides could treat serious conditions triggered by inflammation. Given the therapeutic benefits of the Company’s two flagship products, Ceapro is currently expanding and developing them for use in the nutraceutical industries.

keywords:N/A

$1.7M

Total Funding

46

Number of Employees

$3.6M

Revenue (est)

7%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Ceapro News

2022-04-20 - Lupine Peptides Market Size, Share, Growth 2022-2029| Key ...

Lupine Peptides Market Size, Share, Growth 2022-2029| Key Players – Celsie, Ceapro, Lupina, Lup'ingredients. Market Size And Forecast. New Jersey, USA,- The...

2022-04-17 - Ceapro Inc. Announces Appointment of Geneviève Foster to ...

Rourke, Chairman of the Ceapro Board of Directors. “I see significant potential in Ceapro. The team has done a great job in establishing a base...

2022-04-06 - Ceapro Inc. Reports Fourth Quarter and Full Year 2021 ...

Ceapro Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights. April 13, 2022 09:00 ET | Source: Ceapro Inc. Ceapro Inc...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$6.4M467%N/A
#2
$9M462%N/A
#3
$6.6M46-8%N/A
#4
$9.9M462%N/A
#5
$15M46N/AN/A